Nanexa AB (publ) (FRA:40M)

Market Cap	55.85M +280.6%
Revenue (ttm)	5.17M +19.8%
Net Income	-1.05M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.3085
Previous Close	0.3150
Day's Range	0.3085 - 0.3085
52-Week Range	0.0690 - 0.4300
Beta	n/a
RSI	43.44
Earnings Date	Mar 26, 2026

About Nanexa AB

Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, rest of Europe, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that has completed Phase I trial for the treatment of type 2 diabetes; NEX-18, a depot drug from azacitidine to treat myelodysplastic syndrome; and NEX-20, ...

• Industry: Surgical and Medical Instruments and Apparatus
• Founded: 2007
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 40M

Financial Performance

In 2025, Nanexa AB's revenue was 55.94 million, an increase of 19.80% compared to the previous year's 46.69 million. Losses were -11.39 million, -54.27% less than in 2024.

Financial numbers in SEK